Today: 23 May 2026
Dow Jones futures slip before the open as Fed week and Big Tech earnings crowd the tape
26 January 2026
2 mins read

Dow Jones futures slip before the open as Fed week and Big Tech earnings crowd the tape

New York, January 26, 2026, 05:51 EST — Premarket

  • Dow futures slip 61 points as investors prepare for the Fed’s rate decision and a packed earnings schedule
  • Friday saw the Dow fall 0.58%, weighed down by Intel’s gloomy forecast
  • Traders are focused on U.S. data releases this week, searching for signs on growth and inflation

Dow Jones futures slipped on Monday as investors braced for a busy week featuring a Federal Reserve announcement and earnings from major U.S. firms. The Dow was down 61 points, or 0.12%, trading at 49,202.

The context is crucial since January has been volatile, with the Dow hovering close to its recent peaks. Investors are juggling two demands: evidence that rate cuts remain possible later this year, and confirmation that corporate AI spending is translating into actual sales—not just swelling capex budgets.

Futures track the index ahead of the cash market opening. They often react sharply to headlines, especially during busy weeks packed with policy updates and earnings reports.

The Dow closed Friday down 285.30 points, or 0.58%, at 49,098.71. The S&P 500 ended flat, while the Nasdaq managed a gain. Intel dropped 17% after forecasting quarterly revenue and profit below expectations, dragging on risk appetite. “We’re feeling pretty good, but mindful we might have some significant twists and turns throughout the rest of the year,” said Jason Blackwell, chief investment strategist at Focus Partners Wealth. Reuters

The Dow is feeling pressure from the same “show-me” earnings sentiment, despite most of the AI action centering on the Nasdaq. If the major players offer cautious forecasts, industrial and financial giants in the index might find little refuge.

Outside of stocks, investors are flocking to safe havens. Gold surged beyond $5,000 an ounce, while the yen gained ground amid talks of intervention. That combo has currency markets on edge, complicating things for U.S. multinationals. TD Securities strategist Prashant Newnaha noted, “The market’s inclination is to short the yen but the possibility of coordination means it no longer is a one-way bet.” Reuters

Treasury yields dipped early Monday, with the dollar slipping against major currencies as investors balanced risk and braced for key events this week. Yields are crucial for the Dow—rising borrowing costs can put pressure on industrial and consumer stocks reliant on financing.

U.S. data this week will focus on demand and confidence metrics. Tuesday brings Consumer Confidence figures, followed by Advance Durable Goods on Wednesday. Thursday’s slate includes Personal Income and the PCE deflator—an important inflation measure—plus weekly jobless claims.

The bigger question is whether the Fed can keep markets steady as politics and geopolitics seep into price moves. Investors largely expect the central bank to keep rates unchanged on Wednesday. Fed funds futures — which track bets on the policy rate — still imply at least one quarter-point cut this year. “It’s been a little bit of a short but steep roller-coaster ride over the past several days,” said Yung-Yu Ma, chief investment strategist at PNC Financial Services Group. Reuters

The risk is clear: a hawkish Fed stance, a spike in inflation expectations, or fresh policy news could push yields higher and drag equities down simultaneously. A few disappointing forecasts from key companies would also challenge the optimism priced in right now.

The next major event is the Fed’s policy decision on Wednesday. Traders will zero in on the statement and Chair Jerome Powell’s comments, searching for clues on whether rate cuts will return, and if so, when.

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
UAMY stock jumps nearly 10% in premarket as antimony prices firm and China supply data hits tape
Previous Story

UAMY stock jumps nearly 10% in premarket as antimony prices firm and China supply data hits tape

The Impact of ChatGPT on Mental Health and Wellbeing: AI Therapy Boom Faces a Safety Reckoning
Next Story

The Impact of ChatGPT on Mental Health and Wellbeing: AI Therapy Boom Faces a Safety Reckoning

Go toTop